Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…
The North America Chronic Idiopathic Constipation Drug Market is expected to grow at a CAGR of 6.92%. The market value is expected to rise from $1822 million in 2016 to $3358 million by 2025. The changing modern dietary habits, chances of cancer or other systematic disease leading to CIC and the growing increasing elderly population are some of the factors driving the market.
The North America chronic idiopathic constipation drug market is segmented on the basis of drug types and on the basis of the type of prescriptions. The drug type can be further divided into lubiprostone and linaclotide, with the former being a more popular drug. The prescription drug market can be further segmented into over the counter drugs and prescribed drugs. Continuous government initiatives and the already flourishing healthcare and medical industry in countries such as the United States and Canada are benefiting the CIC market growth in this region.
Some of the major players in the market include Chugai Pharmaceutical, Allergens, Synergy Pharmaceuticals, Ferring International Center S.A., Pfizer, GlaxoSmithKline, Roche Holding Ag, Merck Sharp & Dohme, Sanofi, Bayer Ag, Eli Lilly And Company, Sucampo Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, Theravance Biopharma Inc and Progenics Pharmaceuticals Inc.